Table 7.
Effect of Splenectomy and Pancreatico-splenectomy on morbidity, mortality and oncologic outcome in prospective randomized trials comparing D1- to D2-Lymphadenectomy.
| Country | D1/D1Sple | D2/D2Sple | D1/D1Pancr | D2/D2Pancr | D1/D2 - | -/pancr | -/sple | |
| Mean OS | Holland | 7.37/5.14* | 9.09/5.19* | 7.27/2.34* | 8.81/4.85* | |||
| 15 year OS % (17) | Holland | 22/35* | ||||||
| 5 year OS% (22) | Taiwan | 54/61* | ||||||
| 5 year DSS% (22) | Taiwan | 57/64* | ||||||
| 5 year OS% (19) | UK | 35/39 | 46/33 | 35/13 | 46/25 | 35/46 | 39/24/38 pancr/sple* | |
| Morbidity % (20, 21) | Taiwan | 10.6/35,7* | ||||||
| Morbidity% (18) | UK | 20/44 | 22/59 | 28/- | 30/58 | 28/56* | 28/54* | |
| Mortality % (18) | UK | 4/13 | 6/17 | 6/- | 9/16 | 7/16* | 9/16* | |
D1/D1Sple: D1 vs D1-dissection with splenectomy, D2/D2Sple : D2 vs D2-dissection with splenectomy,
D1/D1Pancr: D1vs D1-dissection with pancreaticosplenectomy, D2/D2Pancr: D2 vs D2-dissection with pancreaticosplenectomy,
D1/D2 - : D1vs D2 both without pancreaticosplenectomy,
pancr: All patients without vs all patients with pancreaticosplenectomy , -/sple: All patients without vs all patients with splenectomy.
*
p < 0.05
OS, overall survival; DSS, Disease Specific Survival.